Weei-Chin Lin, M.D., Ph.D.
Dan L. Duncan Endowed Professor
Positions
- Dan L. Duncan Endowed Professor
-
Medicine-Hematology & Oncology
ÌÇÐÄÊÓÆµ of Medicine
Houston, TX, US
- Professor
-
Department of Molecular and Cellular Biology
ÌÇÐÄÊÓÆµ of Medicine
Houston, Texas, United States
- Dan L Duncan Endowed Professor
-
Dan L Duncan Comprehensive Cancer Center
ÌÇÐÄÊÓÆµ of Medicine
Houston, Texas, United States
- Co-Director
-
Cancer & Cell Biology Graduate Program
ÌÇÐÄÊÓÆµ of Medicine
- Faculty
-
Development, Disease Models & Therapeutics Graduate Program
ÌÇÐÄÊÓÆµ of Medicine
Addresses
- Alkek Building for Biomedical Research (Office)
-
Room: ABBR-R410
Houston, TX, 77030
United States
Education
- PhD from Johns Hopkins University School Of Medicine
- 05/1993 - Baltimore, Maryland, United States
- MD from National Taiwan University
- 06/1986 - Taipei, Taiwan, Taiwan
- Post-Doctoral Fellowship at Johns Hopkins University School of Medicine
- 06/1994 - Baltimore, Maryland, United States
- Residency at Duke University Medical Center
- 06/1996 - Durham, North Carolina, United States
- Clinical Fellowship at Duke University Medical Center
- 06/1999 - Durham, North Carolina, United States
Certifications
- Texas Medical Board
- Diplomate, American Board of Internal Medicine
- Subspecialty in Medical Oncology, ABIM
- Subspecialty in Hematology, ABIM
Honors & Awards
- Dan Duncan Professorship of Oncology
- ÌÇÐÄÊÓÆµ of Medicine (01/2010)
- The Leukemia & Lymphoma Society Scholar
- (07/2006 - 06/2011)
- General Motors Cancer Research Scholar
- (01/2002 - 01/2005)
- Howard Hughes Medical Institute Junior Faculty Development Award
- (06/2001 - 06/2004)
- Damon Runyon-Walter Winchell Physician Scientist Award
- Duke University (04/1999 - 05/2001)
- The Martin and Carol Macht Research Prize
- Johns Hopkins University (05/1993)
Professional Interests
- Cell cycle regulation
- Development of cancer therapeutics
- Clinical hematology
Professional Statement
I am a physician scientist with solid training in both clinical medicine and basic research. My lab is working on fundamental cell cycle/cell death regulation, and protein modifications, particularly focused on the pRb/E2F and p53 pathways in the oncogenic activation. We have identified several important pathways that are deregulated in cancer. My goal is to develop novel cancer therapy based on our own original discoveries.
Selected Publications
-
" ;
-
Kang Liu, Lidija AW Garan, Fang-Tsyr Lin, Weei-Chin Lin. " " Communications Biology. 2025 ; 8(1) (1522)
-
Fang-Tsyr Lin, Kang Liu, Lidija A Wilhelms Garan, Helena Folly-Kossi, Yongcheng Song, Shwu-Jiuan Lin, Weei-Chin Lin. " " Proc Natl Acad Sci U S A. 2023 Oct 25;
Pubmed PMID: . -
Folly-Kossi H, Graves JD, Wilhelms Garan LA, Lin FT, Lin WC.. " " Cancer Res Commun.. 2023 Oct 16; 3 (10) : 2096-112.
Pubmed PMID: .
Intellectual Property
- Method Patent #US 9,636,323 (Approved)
- The present invention provides a method of treating cancer that overexpresses TopBP1 by administering to a patient suffering from the cancer with an effective amount of a small molecule inhibitor that binds the BRCT7/8 domain of TopBP1.
- Co Inventors: Weei-Chin Lin, Pinki Chowdhury, Gregory E. Lin, Kang Liu, Yongcheng Song, Fang-Tsyr Lin
- Product Patent #PCT/US24/48843 (Pending)
- Small molecule inhibitors of TopBP1-BRCT7/8 and uses thereof
- Co Inventors: Weei-Chin Lin, Fang-Tsyr Lin
to edit your profile